Practice guidelines and quality metrics are based on compelling science. The LeAAPS Trial is a pivotal initiative intended to evaluate the safety and effectiveness of surgical LAA exclusion to prevent stroke in patients with an elevated risk, but no history of Afib. Learn more about the groundbreaking study: https://okt.to/BFwYZ3 #ClinicalTrial #stroke #CardiacSurgery
AtriCure, Inc.
Medical Equipment Manufacturing
Mason, Ohio 36,860 followers
We are passionately focused on healing the lives of those affected by Afib and pain after surgery.
About us
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
- Website
-
http://www.atricure.com
External link for AtriCure, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Mason, Ohio
- Type
- Public Company
- Founded
- 2000
- Specialties
- Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
Locations
Employees at AtriCure, Inc.
Updates
-
Hey The Ohio State University students! We’re excited to join you for Diversity Career Day on October 15th. Drop by our booth to explore student opportunities and career paths in the medical device industry. Join an organization that celebrates diversity and inclusivity! Apply early at: https://okt.to/n8civy
-
Physician Assistants, Nurse Practitioners, RN Coordinators, and other healthcare professionals gathered for our Cryo Nerve Block Therapy program today. We delved into the latest standards in analgesia and effective strategies for post-op pain relief, including #cryoNB as part of a multimodal approach. Thank you to all who joined us! Interested in learning more about a non-opioid solution for post-operative pain? Learn more at: https://okt.to/J5fozM #MedEd #cryoNB #PainManagement
-
Congratulations to Dr. James Longoria, M.D. and the Stanford Health Care Tri-Valley team on completing their first case with the AtriClip® FLEX-Mini™ device! Since 2010, Dr. Longoria has performed over 2,000 procedures with an AtriClip device to permanently exclude the LAA. Explore the next-generation AtriClip device, the AtriClip FLEX-Mini: https://okt.to/P5dtpu #AtriClip #LAAE
-
Our manufacturing team is central to our mission. Whether it's on the assembly line or through welding, their exceptional work drives forward our advancements in Afib treatment and post-operative pain management. Join us as Adam Harp, Senior Principal Model Designer, gives an exclusive behind-the-scenes look at what manufacturing at AtriCure is all about. #MFGDay2024
-
At #APHRS2024, the CEASE-AF 24-month results were presented. The data demonstrated that Hybrid ablation with left atrial appendage exclusion is effective over the long term, with a ~33% absolute improvement in freedom from atrial arrhythmias* after 24 months of follow-up in patients with long-standing persistent Afib.** Learn more about the CEASE AF Trial data: https://okt.to/cKo4mY *Freedom from atrial arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia) off anti-arrhythmic drugs (AADs) except previously failed AADs at doses not exceeding those previously failed **Persistent atrial fibrillation with enlarged left atrium and longstanding persistent Afib
-
Introducing the AtriClip® FLEX-Mini™ device. The third-generation and latest addition to our AtriClip® family, it features a closed-ended design that's 60% smaller than the next lowest profile clip on the market – all while maintaining continual parallel closing pressure and stability that AtriClip devices are known for. Learn how the FLEX-Mini could elevate your practice: https://okt.to/nTWM6C
-
Patients with Inappropriate Sinus Tachycardia (IST) often experience symptoms that significantly impact their quality of life. For those who don’t respond to or are intolerant to medications, the HEAL-IST clinical trial is evaluating a new hybrid ablation procedure as a potential treatment. Learn more about the study: heal-ist.com #ClinicalTrial #IST #Innapropriatesinustachycardia
-
In a retrospective analysis sponsored by AtriCure, healthcare systems saved an average of $8,601 in total healthcare costs for lobectomy patients who received Cryo Nerve Block (ablation) for post-op pain management compared to those who did not. Learn more about the device reducing hospital system costs and relieving post-op pain at: https://okt.to/auKl0L
-
We're excited to share the Isolator® Synergy™ EnCompass® Clamp has received regulatory approval in CE-marked countries in Europe! AtriCure’s portfolio of bipolar radiofrequency (RF) ablation devices have been used in over 575,000 cases, backed by continuous innovation, clinical science, and education. The EnCompass clamp is our latest RF device providing a simpler and faster approach to ablating the heart in open-chest procedure. Read the full release to learn more: https://okt.to/Qntpc3